circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
The dermal papillae (DP; singular papilla, diminutive of Latin papula, 'pimple') are small, nipple-like extensions (or interdigitations) of the dermis into the epidermis. At the surface of the skin in hands and feet, they appear as epidermal, papillary or friction ridges (colloquially known as fingerprints). Note that dermal papilla has two meanings referring to separate anatomical features. The dermal papilla of the dermal–epidermal junction should not be confused with the dermal papilla cells at the base of each hair follicle. The pattern of ridges produced in hands and feet are only partly genetically determined features that are developed before birth, the timing and events around the ridge formation area also contributing. They remain substantially unaltered (except in size) throughout life, and therefore determine the patterns of fingerprints, making them useful in certain functions of personal identification. The dermal papillae are part of the uppermost layer of the dermis, the papillary dermis, and the ridges they form greatly increase the surface area between the dermis and epidermis. Because the main function of the dermis is to support the epidermis, this greatly increases the exchange of oxygen, nutrients, and waste products between these two layers. Additionally, the increase in the surface area prevents the dermal and epidermal layers from separating by strengthening the junction between them. With age, the papillae tend to flatten and sometimes increase in number.
Hide glue is made from animal hide (animal skin) and is often used in woodworking. It may be supplied as granules, flakes, or flat sheets, which have an indefinite shelf life if kept dry. It is dissolved in water, heated and applied warm, typically around 60 °C (140 °F). Warmer temperatures quickly destroy the strength of hide glue. Commercial glue pots, simple water baths or double boilers may be used to keep the glue hot while in use. As hide glue cools, it gels quickly. At room temperature, prepared hide glue has the consistency of stiff gelatin, which is in fact a similar composition. Gelled hide glue does not have significant strength, so it is vital to apply the glue, fit the pieces, and hold them steady before the glue temperature drops much below 50 °C (120 °F). All glues have an open time, the amount of time the glue remains liquid and workable. Joining parts after the open time is expired results in a weak bond. Hide glue's open time is usually a minute or less. In practice, this often means having to heat the pieces to be glued, and gluing in a very warm room, though these steps can be dispensed with if the glue and clamp operation can be carried out quickly. Where hide glue is in occasional use, excess glue may be held in a freezer, to prevent spoilage from the growth of microorganisms. Hide glue has some gap filling properties, although modern gap-filling adhesives, such as epoxy resin, are better in this regard. Hide glue that is liquid at room temperature is also possible through the addition of urea.
=== Comparison to similar agents === The clinical effectiveness of methocarbamol compared to other muscle relaxants is not well known. One trial of methocarbamol versus cyclobenzaprine, a well-studied muscle relaxant, in those with localized muscle spasm found there were no significant differences in their effects on muscle spasm, limitation of motion, or limitation of daily activities.
This side effect is mediated by the metabolite norfenfluramine on 5HT2B receptors of heart valves, leading to a characteristic pattern of heart failure following proliferation of cardiac fibroblasts on the tricuspid valve. Both fenfluramine and benfluorex form norfenfluramine as a metabolite. This side effect led to the withdrawal of fenfluramine as an anorectic drug worldwide, and later to the withdrawal of benfluorex in Europe.
Sources: en.wikipedia.org
== See also == Bruise, which is a hematoma caused by trauma Purpura secondary to clotting disorders Purpura hemorrhagica in horses Pigmented purpuric dermatosis Schamberg disease (progressive pigmentary purpura)
Retatrutide (LY-3437943) is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.
Peyronie's disease (PD) is a benign, acquired penile connective tissue disease characterized by the occurrence of fibrotic plaques within the tunica albuginea—the dense elastic covering of the corpora cavernosa. The plaques cause abnormal curvature, pain, penile deformities (e.g., narrowing or indentation), and usually erectile dysfunction, particularly during erection. The condition typically leads to significant sexual and psychological effects, including difficulty with penetration and lowered self-esteem or evasiveness. Peyronie's disease is most often seen in middle-aged and older men with a median age of onset between 55 and 60 years, however, it has also been reported in adolescents. While the etiology of Peyronie's disease is still uncertain, the leading hypothesis is that it arises from dysregulated wound healing in response to chronic microtrauma of the erect penis. This triggers a cascade of profibrotic molecular pathways—most notably overexpression of transforming growth factor-beta 1 (TGF-β1)—that end in fibroblast proliferation, myofibroblast differentiation, and overproduction of type I collagen. Genetic predisposition is supported by family clustering and linkage with systemic fibrosing disorders such as Dupuytren's contracture. Risk factors include age, penile injury, diabetes mellitus, and cigarette smoking. The prevalence of Peyronie's disease has been projected at 1% to 20% among the general population of men increasing with age and comorbidities such as erectile dysfunction (ED) or connective tissue disease.
Navy expeditions continued to be plagued by scurvy even while fresh (not jerked or tinned) meat was well known as a practical antiscorbutic among civilian whalers and explorers in the Arctic. In the latter half of the 19th century, there was greater recognition of the value of eating fresh meat as a means of avoiding or treating scurvy, but the lack of available game to hunt at high latitudes in winter meant it was not always a viable remedy. Criticism also focused on the fact that some of the men most affected by scurvy on Naval polar expeditions had been heavy drinkers, with suggestions that this predisposed them to the condition. Even cooking fresh meat did not destroy its antiscorbutic properties, especially as many cooking methods failed to bring all the meat to high temperature. The confusion is attributed to several factors:
Because it is often undiagnosed or misdiagnosed in childhood, some instances of EDS have been mischaracterized as child abuse. The pain may also be misdiagnosed as a behavior disorder or Munchausen by proxy. The pain associated with EDS ranges from mild to debilitating.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.